MA06.04 Phase II Study of Durvalumab Plus Concurrent Radiotherapy in Unresectable Locally Advanced NSCLC: DOLPHIN Study (WJOG11619L)

Abstract

Durvalumab after concurrent chemoradiotherapy (cCRT) has been standard of care with unresectable locally advanced (LA) non-small cell lung cancer (NSCLC) (stage III /postoperative recurrent NSCLC). But, some patients are unable to complete cCRT and cannot receive durvalumab. Immunotherapy plays an important role in NSCLC and combination of radiotherapy and immunotherapy have been reported to have a synergistic effect. Here, we reported on DOLPHIN study (JapicCTI- 194840), the first phase II study to evaluate the efficacy and safety of durvalumab plus concurrent curative radiation therapy for PD-L1-positive unresectable LA-NSCLC without chemotherapy.